AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00712465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Tablet, repeated administration
Study NCT04129788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 5 milligram
Description: three doses taken, one per day on three consecutive days
Study NCT04129788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: three doses taken, one per day on three consecutive days
Study NCT01617057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiludronic acid
Description: 400 mg / day for 3 months
Study NCT01617057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg / day for 3 month
Study NCT03246113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
Study NCT03246113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral alkylating agent with demonstrated antitumor activity.
Study NCT03246113 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
Study NCT02076828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferro Sanol® sp
Description: The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Study NCT02076828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Santafer® sp.
Description: The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Study NCT02076828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferro Zinc® sp
Description: The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Study NCT03684915 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotary files
Description: using rotary files in cleaning root canals of infected primary molars
Study NCT03684915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotary files
Description: using rotary files in cleaning root canals of infected primary molars
Study NCT02439320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Study NCT02439320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Study NCT02439320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matches lasmiditan doses)
Study NCT02439320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matches lasmiditan doses)
Study NCT04564612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm
Study NCT04564612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Administered as specified in the treatment arm
Study NCT04564612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered as specified in the treatment arm
Study NCT01959620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-Session Exposure Therapy
Description: One exposure therapy session lasting one hour
Study NCT01959620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-Session Exposure Therapy
Description: Three exposure therapy sessions lasting one hour each, delivered one week apart
Study NCT01100099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten challenge.
Description: The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
Study NCT02928510 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection
Study NCT02928510 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Undergo colonoscopy
Study NCT03240783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham Injection and/or oral placebo
Description: The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
Study NCT02928510 — intervention group
Intervention type: PROCEDURE
Intervention: Colposcopic Biopsy
Description: Undergo colposcopic biopsy
Study NCT02928510 — intervention group
Intervention type: DRUG
Intervention: Idelalisib
Description: Given PO
Study NCT02928510 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02928510 — intervention group
Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02928510 — intervention group
Intervention type: PROCEDURE
Intervention: Physical Examination
Description: Undergo physical examination
Study NCT02928510 — intervention group
Intervention type: PROCEDURE
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy
Study NCT02302651 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MR guided High Intensity focused ultrasound
Description: High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
Study NCT04068103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT04068103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04068103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT04068103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT04068103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Give IV
Study NCT04068103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo active surveillance
Study NCT04068103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo active surveillance
Study NCT04235244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermo mechanical device
Description: The thermomechanical-analgesia device will be placed and operated 30 seconds before the injection into the abdominal area,and injection will be applied by sliding the device to the side of the selected region during the injection,
Study NCT03833765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+XCM
Description: After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.
Study NCT03833765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF alone
Description: Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
Study NCT00773344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanespimycin
Description: Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)
Study NCT02734784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
Study NCT02734784 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Photodynamic Therapy
Description: After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
Study NCT00413283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
Study NCT04235244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local coolant spray
Description: Coolant spray will be applied to the abdominal area for 5 seconds at a distance of 15 cm.
Study NCT04235244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ıce battery
Description: abdominal bölgeye uygulamadan önce ve sonra 5 dk. lokal soğuk uygulama
Study NCT03646994 — intervention group
Intervention type: DRUG
Intervention: Crizotinib
Description: Crizotinib Cap 250 mg po bid
Study NCT03337399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped PC
Description: Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer
Study NCT03337399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Integrated PC
Description: Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer
Study NCT02844296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about exercise
Description: Video about short-bout exercise will be played for the participants.
Study NCT02844296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App about exercise
Description: A smartphone App about exercise will be installed in participants' mobile phone.
Study NCT02844296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet about exercise
Description: A leaflet about exercise will be provided for the participants.
Study NCT02844296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about diet
Description: Video about healthy diet will be played for the participants.
Study NCT02844296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App about diet
Description: A smartphone App about healthy diet will be installed in participants' mobile phone.
Study NCT02844296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet about diet
Description: A leaflet about healthy diet will be provided for the participants.
Study NCT00116558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early NIPPV
Description: Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
Study NCT00116558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard NIPPV
Description: Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
Study NCT03307733 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: walking and behavour change techniques
Description: a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
Study NCT04626869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Diaphragm Movement
Description: Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
Study NCT00829881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine Hydrochloride
Description: A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
Study NCT00829881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: A single placebo capsule
Study NCT01232296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: 500 mg p.o. o.d. 5 days on/2 days off
Study NCT01232296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg p.o. b.i.d.
Study NCT03211949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary block
Description: 2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
Study NCT03211949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scandicaine
Description: 2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
Study NCT01343563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trigeminal Nerve Stimulation
Description: External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
Study NCT00413283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection.
Study NCT00413283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous infusion
Study NCT00413283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion
Study NCT00413283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Intravenous infusion
Study NCT00413283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion
Study NCT00413283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Intravenous infusion
Study NCT00413283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion
Study NCT02144883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
Study NCT02144883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help materials
Description: All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
Study NCT02144883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help materials
Description: All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
Study NCT00778609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027)
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
Study NCT00778609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Encapsulated Microgynon + Placebo
Description: Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
Study NCT06501521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
Study NCT00695864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron and Placebo crossover
Study NCT02972658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study NCT01626833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOMATROPINE* : Norditropine® simplexx®
Description: SOMATROPINE\* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
Study NCT01626833 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
Study NCT01377844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGT0001442
Study NCT01377844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00549666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg
Description: Lurasidone 40 mg days 12-21 once daily
Study NCT00549666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 40 mg
Description: Placebo 40 mg once daily during treatment period
Study NCT00549666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen
Description: Ortho Tri-Cyclen during 28-day lead in period
Study NCT03072745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning